ArticleCanadian journal of gastroenterology = Journal canadien de gastroenterologie2011
Assessing inflammatory bowel disease-associated antibodies in Caucasian and First Nations cohorts.
Article in Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03262649 (Manitoba Inflammatory Bowel Disease Cohort Study), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Manitoba Inflammatory Bowel Disease Cohort Study
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Inflammatory Bowel Disease in Indigenous Populations: A Scoping Review.Crohn's & colitis 360 · 2025Article
- Diagnostic Procedures for Inflammatory Bowel Disease: Laboratory, Endoscopy, Pathology, Imaging, and Beyond.Diagnostics (Basel, Switzerland) · 2024Review
- Circulating Fibroblast Activation Protein as Potential Biomarker in Patients With Inflammatory Bowel Disease.Frontiers in medicine · 2021Article
- Proteomic insights on the metabolism in inflammatory bowel disease.World journal of gastroenterology · 2020Review
- Ulcerative colitis: understanding its cellular pathology could provide insights into novel therapies.Journal of inflammation (London, England) · 2020Review
- Role of Anti-Carbamylated Protein Antibodies Compared to Anti-Citrullinated Protein Antibodies in Indigenous North Americans With Rheumatoid Arthritis, Their First-Degree Relatives, and Healthy Controls.Arthritis & rheumatology (Hoboken, N.J.) · 2016Article
- Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease.World journal of gastrointestinal pharmacology and therapeutics · 2016Review
- Intraluminal Flagellin Differentially Contributes to Gut Dysbiosis and Systemic Inflammation following Burn Injury.PloS one · 2016Article
- Article
- Epidemiology and risk factors for IBD.Nature reviews. Gastroenterology & hepatology · 2015Review
- Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies.World journal of gastroenterology · 2014Review
- Biomarkers of inflammatory bowel disease.Disease markers · 2014Review
- Inflammatory bowel disease serology in Asia and the West.World journal of gastroenterology · 2013Article
- Familial and ethnic risk in inflammatory bowel disease.Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundFirst Nation populations in Canada have a very low incidence of inflammatory bowel disease (IBD). Based on typical infections in this population, it is plausible that the First Nations react differently to microbial antigens with a different antibody response pattern, which may shed some light as to why they experience a low rate of IBD.
objectiveTo compare the positivity rates of antibodies known to be associated with IBD in Canadian First Nations compared with a Canadian Caucasian population.
methodsSubjects with Crohn's disease, ulcerative colitis (UC), rheumatoid arthritis (RA) (as an immune disease control) and healthy controls without a personal or family history of chronic immune diseases, were enrolled in a cohort study aimed to determine differences between First Nations and Caucasians with IBD or RA. Serum from a random sample of these subjects (n=50 for each of First Nations with RA, First Nations controls, Caucasians with RA, Caucasians with Crohn's disease, Caucasians with UC and Caucasians controls, and as many First Nations with either Crohn's disease or UC as could be enrolled) was analyzed in the laboratory for the following antibodies: perinuclear antineutrophil cytoplasmic antibody (pANCA), and four Crohn's disease-associated antibodies including anti-Saccharomyces cerevisiae, the outer membrane porin C of Escherichia coli, I2 - a fragment of bacterial DNA associated with Pseudomonas fluorescens, and the bacterial flagellin CBir-1. The rates of positive antibody responses and mean titres among positive results were compared.
resultsFor pANCA, First Nations had a positivity rate of 55% in those with UC, 32% in healthy controls and 48% in those with RA. The pANCA positivity rate was 32% among Caucasians with RA. The rates of the Crohn's disease-associated antibodies for the First Nations and Caucasians were comparable. Among First Nations, up to one in four healthy controls were positive for any one of the Crohn's disease-associated antibodies. First Nations had significantly higher pANCA titres in both the UC and RA groups than Caucasians. DISCUSSION: Although First Nation populations experience a low rate of IBD, they are relatively responsive to this particular antibody panel.
conclusionsThe positivity rates of these antibodies in First Nations, despite the low incidence of IBD in this population, suggest that these antibodies are unlikely to be of pathogenetic significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.